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Background: Renal transplant recipients frequently experience neurological complications. Whereas ischemic
stroke, cerebral haemorrhage or hypertensive encephalopathy often result from vascular alterations prior to
transplantation, other cerebral diseases like CNS infections, primary brain tumors and drug induced neurotoxicity
may develop as consequences of the required post-transplant immunosuppressive treatment.
Case presentation: Here we report on an unusual clinical course of a young kidney transplant recipient with a
cluster of fulminant necrotic brain lesions within a period of two months due to thrombotic microangiopathy.
Conclusion: Cerebral ischemia in organ transplant recipients should prompt one to consider thrombotic microangiopathy.
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Neurological complications post transplantation include
infections and tumours promoted by the immunosuppres-
sive therapy in general and more frequently, tremor and
peripheral neuropathies which are commonly related to
the therapy with calcineurin inhibitors [1]. Severe calcine-
urin inhibitor-related side effects occur in 10% and are,
mostly, reversible after dose reduction or cessation of
the drug. These include decreased responsiveness, hal-
lucinations, delusions, seizures, cortical blindness, and
stroke-like episodes [2]. Rarely, calcineurin inhibitor re-
lated neurotoxicity presents as so-called “reversible
posterior leukoencephalopathy” (RLPS) [3].Case presentation
A 25-year-old male caucasian patient presented with a
1-week history of left-sided weakness, preceded by gen-
eral fatigue and progressive forgetfulness in the previous
two months. His medical history comprised a kidney
transplantation 12 years earlier for end-stage renal fail-
ure due to focal and segmental glomerulosclerosis, a* Correspondence: haghikia.arash@mh-hannover.de
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reproduction in any medium, provided the orlongstanding well-controlled hypertension (RR 130/
85 mmHg in the previous months), mild pancytopenia
with a previous diagnosis of a hypoplastic bone marrow
with presumed toxic cause. At admission, his therapy in-
cluded cyclosporine A 35 mg b.i.d, prednisolone 7.5 mg,
valsartan 160 mg b.i.d and 40 μg darbepoetin alfa every
two weeks. Arterial blood pressure at admission was 129/
90 mmHg and body temperature was normal. The strength
of the left-sided limbs was mildly decreased (4+/5). Ini-
tially, leucocytopenia and mild thrombopenia, a haemoglo-
bin concentration of 11 g/dl and normal C-reactive protein
were present (Table 1). The serum creatinine concentration
was 156 μmol/l (equaling an eGFR of 47 ml/min) which
was in line with values of the preceding years. Actual and
previous values for lactate dehydrogenase were normal
(238 U/l).
A cranial MRI showed right-sided temporo-parietal and
thalamic lesions (Figure1A). Correspondingly, MR angiog-
raphy revealed a missing flow signal of the right middle
cerebral artery (Figure 1B). Cardiac thromboembolism was
excluded by transesophageal echocardiography. By Doppler
ultrasonography and MR angiography, arterial occlusive
disease, vasculitis and aneurysms of the extracranial
brain-supplying arteries and of the aorta were excluded.
Vasculitits was further excluded by negative results for anti-
nuclear antibodies, ANCA, anti-mitochondrial antibodies,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 Depicts the course of some laboratory values




Hemoglobin (g/dl) 11 11.1 8.8
White blood cells (thousand/μl) 3.9 0.7 4.0
Platelets (thousand/μl) 168 265 15
Creatinine (μmol/l) 156 161 124
CRP (mg/l) 6 4 4
LDH (U/l) 238 198 601
Cyclosporin A level (μg/l). 64 < 15 <15
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status. Acetyl salicylic acid was prescribed and the patient
was discharged.
Four weeks later he was admitted again because of list-
lessness and mutism. At this admission leucopenia had
progressed to 0.7 thousand/μl, the haemoglobin concen-
tration was 11.1 g/dl and the thrombocyte count 200
thousand/μl. The serum creatinine concentration was
161 μmol/l and the cyclosporine A trough level (measured
by mass spectrometry; LC-MS/MS) was below the detec-
tion limit (15 μg/l) (Table 1). A bone marrow examination
revealed hypoplasia with dysmature haematopoiesis. An
electroencephalogram displayed left-sided fronto-temporalFigure 1 Cranial MR Imaging of the cerebral lesions. (A) Initial
cranial MRI demonstrating right-sided temporo-parietal and thalamic
lesions of different age. (B) MR angiography depicting missing flow
signal of the right middle cerebral artery.intermittent rhythmic delta-activity without epileptiform
discharges. The cerebrospinal fluid (CSF) was normal in-
cluding virology (CMV, HSV, VZV, EBV, enterovirus and
JCV). Moreover, repeatedly negative results of CRP and
normal body temperature argued against an infection.
At the 5th day, he was discovered having bilateral
blindness accompanied by moderate to severe loss of
conscious (Glascow coma scale of 8) within the next two
days. At the onset of these symptoms cyclosporine A
was paused. A follow-up cranial MRI revealed new
ischemic lesions of the left-sided thalamus and both oc-
cipital regions. Brain biopsy was decided and the histology
showed extensive necrosis and arteriolar hyalinosis. No
findings of vasculitis, inflammatory, infectious (negative
tests for CMV, HSV, VZV, EBV and JCV) or neoplastic
processes were detected. In the next two days the patient
increasingly developed severe hypertension with systolic
values above 220 mmHg. Three days after the brain biopsy
thrombocyte count rapidly declined to 25 thousand/μl.
Schistocytes remained negative and ADAMTS-13 activity
and C3c, C4 and CH50 complement titers were normal
but lactate dehydrogenase increased to 550 U/l. A cranial
CT-scan (Figure 2) demonstrated bilateral infarct lesions
in the posterior circulation territory. The patient was
transferred for anti-hypertensive treatment to the
ICU, where he died after developing further cerebral
infarctions of the brain stem. Post-mortem examin-
ation revealed disseminated thrombotic microangiop-
athy in the brain, the lungs and the renal allograft
(Figure 3).Figure 2 A cranial CT-scan at a later stage of disease demonstrated
additional bilateral infarct lesions in the posterior circulation
territory.
Figure 3 Postmortem diagnosis of thrombotic microangiopathy. Intravascular thrombi are indicated by arrows. A: pre-glomerular arteriole of
the transplanted kidney; B: arteriole in the brain tissue; and thombi in a smaller (C) and in a larger arterial (D) vessel of the lung. PAS staining
(A, B), HE staining (C, D), magnification x400.
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The prevalence of acute cerebral ischemia among renal
transplant recipients has been estimated at 8% [4]. Ar-
teriosclerotic vascular disease or hypertensive encephal-
opathy was unlikely causative in this young patient
because of the absence of relevant risk factors. Also, ar-
terial thromboembolism was definitely ruled out. CNS
infection which comprise about 40% of all cerebral com-
plications and are mostly seen during the first 24 months
post transplantation [5], was not evident in our patient
Although calcineurin inhibitors have emerged as a fre-
quent cause of neurologic symptoms and disease, affecting
25% to 59% of transplant patients, gross infarction is typic-
ally not seen with these compounds [2]. In our patient,
previous cyclosporine trough levels were consistently very
low and no clinical improvement was achieved after stop-
ping cyclosporine A treatment. Nevertheless, this does not
completely argue against cyclosporine A-induced vascular
injury because high calcineurin-inhibitor levels appear to
be not a pre-requisite and cessation of the drug in our pa-
tient may have been too late to change the course of
disease.
Another complication which may be attributed to
cyclosporine A is thrombotic microangiopathy (TMA)
[6]. A study by Zarifian et al. reviewing 188 patientsreported TMA as the cause of renal graft dysfunction in
14% of renal graft recipients and 92% of the TMA cases
were on therapy with cyclosporine A [7]. Noteworthy,
conversion from cyclosporine A to tacrolimus resulted
in salvage of graft function in 81% of the cases. Onset of
TMA was highly variable with 4 days to 2190 days post-
transplantation, suggesting that other precipitating fac-
tors besides cyclosporine A may have been present in
some patients. In none of the patients, extrarenal in-
volvement of TMA was reported. In our case, postmor-
tal histopathological examination clearly showed signs
of TMA in the brain, in the lungs and in the renal trans-
plant. Early recognition of TMA in our patient was
impeded as the initial biopsy did not report TMA as the
cause of brain necrosis, mild pancytopenia was pre-
existing and clear signs of thrombotic microangiopathy
with hemolysis were missing until major cerebral dam-
age had occurred. Also, in our patient there was no clue
for TMA in the former history with regard to his ori-
ginal renal disease, in an allograft biopsy performed two
years before his death, or in his family. As diarrhoea was
not present at any time we did not include infectious
haemolytic uremic syndrome in our differential diagno-
sis. Unfortunately, we could not perform thorough com-
plement gene analysis in this short disease course to
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was causative for the TMA. Nevertheless, C3c, C4 and
CH50 complement titers were normal at the time of
presentation.
This case emphasizes that TMA can take a smoulder-
ing course in transplant patients without typical signs
like severe thrombopenia or the characteristic picture of
haemolytic-uremic syndrome with severe anemia and
renal dysfunction. Earlier intervention may have had
changed the course in our patient. Although there is no
proof that cyclosporine A was causative, prompt with-
drawal may have been beneficial. Plasmapheresis has
been the mainstay in the treatment of TMA. Improved
allograft outcomes have been reported particularly with
pre-emptive plasmapheresis therapy in patients with
known risk for atypical haemolytic uremic syndrome [8].
More recently, eculizumab has emerged as an efficacious
therapy in such patients, either with or without plasma-
pheresis treatment [9]. Yet, at the point where TMA
with a possible underlying diagnosis of atypical haemo-
lytic uremic syndrome had to be considered in our pa-
tient, the cerebral infarction was advanced excluding a
relevant improvement by this therapy.
Written informed consent was from the parents of the
patient for the publication of this report and any accom-
panying images.
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